Vyant Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plans - Effects of Stock-Based Compensation Related to Stock Option Awards (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 696,353us-gaap_ShareBasedCompensation	$ 530,122us-gaap_ShareBasedCompensation
Cost of Revenues [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	49,186	20,412
Research and Development [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	95,073	14,102
General and Administrative [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	520,737	468,855
Sales and Marketing [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 31,357	$ 26,753